Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Una terapia experimental con células madre para regenerar córneas muestra un 92 % de éxito en la recuperación de la visión.

Blind No More? Revolutionary Stem Cell Therapy Restores Vision With 92% Success

04 de marzo de 2025

Una terapia experimental con células madre desarrollada en el Mass Eye and Ear del centro médico y de investigación Mass General Brigham, la cual han denominado CALEC, ha demostrado tener un 92 % de éxito en la regeneración de córneas y la recuperación de la visión. CALEC consiste en el trasplante de células madre cultivadas en laboratorio del ojo sano de un paciente, a una córnea dañada. El ensayo confirmó su seguridad y eficacia, con mejoras significativas en la visión. De acuerdo con los autores, aunque todavía se encuentra en fase experimental, los investigadores aspiran a la aprobación de la FDA y a futuros tratamientos con células madre de donantes para ampliar la accesibilidad.